Innate Pharma Stock price

Equities

IPH

FR0010331421

Biotechnology & Medical Research

Real-time Euronext Paris 07:57:54 2024-03-28 am EDT 5-day change 1st Jan Change
2.2 EUR +0.46% Intraday chart for Innate Pharma +1.38% -16.03%
Sales 2023 61.64M 66.52M Sales 2024 * 47.99M 51.78M Capitalization 177M 191M
Net income 2023 -7M -7.55M Net income 2024 * -29M -31.3M EV / Sales 2023 3.43 x
Net cash position 2023 * 29.41M 31.74M Net cash position 2024 * 25.2M 27.19M EV / Sales 2024 * 3.16 x
P/E ratio 2023
-29.1 x
P/E ratio 2024 *
10.4 x
Employees 191
Yield 2023 *
-
Yield 2024 *
-
Free-Float 75.5%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.46%
1 week+1.38%
Current month+0.69%
1 month-6.78%
3 months-14.06%
6 months-13.39%
Current year-16.03%
More quotes
1 week
2.15
Extreme 2.15
2.22
1 month
2.12
Extreme 2.12
2.40
Current year
2.12
Extreme 2.12
2.80
1 year
2.11
Extreme 2.11
3.35
3 years
1.99
Extreme 1.986
8.30
5 years
1.99
Extreme 1.986
8.30
10 years
1.99
Extreme 1.986
17.85
More quotes
Managers TitleAgeSince
Founder 59 99-09-22
Chief Executive Officer 62 99-09-22
Director of Finance/CFO 49 21-03-31
Members of the board TitleAgeSince
Chief Executive Officer 62 99-09-22
Director/Board Member 72 07-06-25
Director/Board Member 54 10-05-24
More insiders
Date Price Change Volume
24-03-28 2.2 +0.46% 17 179
24-03-27 2.19 -0.23% 53,254
24-03-26 2.195 +0.69% 26,812
24-03-25 2.18 +0.69% 32,842
24-03-22 2.165 -0.23% 25,864

Real-time Euronext Paris, March 28, 2024 at 04:07 am EDT

More quotes
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - revenues from collaboration and licensing agreements (86%); - government financing for research expenditure (13.9%); - other (0.1%). At the end of 2022, the company had a portfolio of 5 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 2 in phase I (IPH5301 for the treatment of solid tumours and IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia), and 7 in preclinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.19 EUR
Average target price
6.27 EUR
Spread / Average Target
+186.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Innate Pharma - Euronext Paris